Drug Design, Development and Therapy (May 2021)
Forkhead Box Protein O1: Functional Diversity and Post-Translational Modification, a New Therapeutic Target?
Abstract
Xiaojun Zhang,1 Lusheng Jiang,2 Huimin Liu3 1Department of Cardiology, Shandong Rongjun General Hospital, Jinan, 250013, People’s Republic of China; 2Department of Emergency, Shandong Rongjun General Hospital, Jinan, 250013, People’s Republic of China; 3Blood Purification Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, People’s Republic of ChinaCorrespondence: Huimin LiuBlood Purification Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, No. 42, Wenhua West Road, Lixia District, Jinan, 250011, Shandong Province, People’s Republic of ChinaTel +86 531 6861 7808Email [email protected]: Forkhead box protein O1 (FoXO1) is a transcription factor involved in the regulation of a wide variety of physiological process including glucose metabolism, lipogenesis, bone mass, apoptosis, and autophagy. FoXO1 dysfunction is involved in the pathophysiology of various diseases including metabolic diseases, atherosclerosis, and tumors. FoXO1 activity is regulated in response to different physiological or pathogenic conditions by changes in protein expression and post-translational modifications. Various modifications cooperate to regulate FoXO1 activity and FoXO1 target gene transcription. In this review, we summarize how different post-translational modifications regulate FoXO1 physiological function, which may provide new insights for drug design and development.Keywords: forkhead box protein O1, post-translational modification, transcription
